US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Eupraxia Pharmaceuticals

6.00

-0.2800-4.46%

Post-market: 6.300.3000+5.00%16:59 EST

Volume:227.30K

Turnover:1.39M

Market Cap:303.89M

PE:-6.82

High:6.82

Open:6.26

Low:5.95

Close:6.28

52wk High:7.19

52wk Low:2.68

Shares:50.65M

Float Shares:39.63M

Volume Ratio:2.15

T/O Rate:0.57%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-0.8798

EPS(LYR):-0.7642

ROE:-61.02%

ROA:-36.21%

PB:5.21

PE(LYR):-7.85

Loading ...

Overview Company News Filings

Eupraxia Pharmaceuticals Up Nearly 16%, on Pace for Largest Percent Increase Since November 2024 -- Data Talk

Eupraxia Pharmaceuticals Q3 EPS $(0.19) Beats $(0.21) Estimate

Eupraxia Pharmaceuticals Reports Third Quarter 2025 Financial Results

Eupraxia Pharmaceuticals Releases Q3 2025 Financial Results

Eupraxia Pharmaceuticals Advances EoE Treatment with EP-104GI Trial

Eupraxia Pharmaceuticals Reports Positive Results in EoE Trial and Plans Expansion

Raymond James Sticks to Their Buy Rating for Eupraxia Pharmaceuticals (EPRX)

Eupraxia Pharmaceuticals Closes $80.5 Million Public Offering

Eupraxia Pharmaceuticals Announces Positive Data from Highest-Dose Cohort in the Ongoing RESOLVE Trial in Eosinophilic Esophagitis, and Plans for Expansion of EP-104GI Development Programs

Eupraxia Pharmaceuticals Closes $80.5 Million Public Offering

MT Newswires Live

Eupraxia Pharmaceuticals Down Over 7%, on Pace for Largest Percent Decrease Since March 2024 -- Data Talk

Eupraxia Pharmaceuticals Prices $70 Million Public Offering

Eupraxia Pharmaceuticals 12.727M share Spot Secondary priced at $5.50

Eupraxia Pharmaceuticals Proposes Public Offering

MT Newswires Live

Eupraxia Pharmaceuticals announces common shares offering, no amount given

Eupraxia Pharmaceuticals Announces Proposed Public Offering of Common Shares

Eupraxia Pharmaceuticals Appoints New CFO Amid Leadership Transition

First Set of 1-Year Clinical Results from RESOLVE Trial in Eosinophilic Esophagitis (EoE), Durable and Sustained Symptom & Tissue Responses after Dosing with EP-104GI

Eupraxia Pharmaceuticals Price Target Maintained With a $12.00/Share by HC Wainwright & Co.

Eupraxia Pharmaceuticals Q2 EPS $(0.26) Misses $(0.19) Estimate

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/EPRX/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"EPRX","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"EPRX\",,,,,undefined,":{"symbol":"EPRX","market":"US","secType":"STK","nameCN":"Eupraxia Pharmaceuticals","latestPrice":6,"timestamp":1765227600000,"preClose":6.28,"halted":0,"volume":227295,"hourTrading":{"tag":"盘后","latestPrice":6.3,"preClose":6,"latestTime":"16:59 EST","volume":51,"amount":306.2999973,"timestamp":1765231191835},"delay":0,"floatShares":39629000,"shares":50648331,"eps":-0.879812,"marketStatus":"Post-Mkt","change":-0.28,"latestTime":"12-08 17:55:54 EST","open":6.26,"high":6.8159,"low":5.95,"amount":1386522.911385,"amplitude":0.137882,"askPrice":6.98,"askSize":2500,"bidPrice":4.95,"bidSize":100,"shortable":3,"etf":0,"ttmEps":-0.879812,"tradingStatus":3,"nextMarketStatus":{"tag":"Closed","tradingStatus":0,"beginTime":1765242000000},"marketStatusCode":4,"adr":0,"listingDate":1712289600000,"exchange":"NASDAQ","adjPreClose":6.28,"postHourTrading":{"tag":"盘后","latestPrice":6.3,"preClose":6,"latestTime":"16:59 EST","volume":51,"amount":306.2999973,"timestamp":1765231191835},"volumeRatio":2.148399},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"EPRX\",,,,,undefined,":{"symbol":"EPRX","floatShares":39629000,"roa":"-36.21%","roe":"-61.02%","lyrEps":-0.764151,"volumeRatio":2.148399,"shares":50648331,"dividePrice":0,"high":6.8159,"amplitude":0.137882,"preClose":6.28,"low":5.95,"week52Low":2.6801,"pbRate":"5.21","week52High":7.19,"institutionHeld":0,"latestPrice":6,"committee":-0.923077,"eps":-0.879812,"divideRate":0,"volume":227295,"delay":0,"ttmEps":-0.879812,"open":6.26,"prevYearClose":3.17,"prevWeekClose":6.28,"prevMonthClose":6.21,"prevQuarterClose":5.9,"fiveDayClose":5.97,"twentyDayClose":5.45,"sixtyDayClose":5.315},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/EPRX\",params:#limit:5,,,undefined,":[{"market":"US","date":"2025-11-04","symbol":"EPRX","fiscalQuarterEnding":"2025/09","expectedEps":-0.23,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1762232400000,"reportTimeType":"post","actualEps":-0.19},{"market":"US","date":"2025-08-12","symbol":"EPRX","fiscalQuarterEnding":"2025/06","expectedEps":-0.21,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1754971200000,"reportTimeType":"post","actualEps":-0.26},{"market":"US","date":"2025-05-06","symbol":"EPRX","fiscalQuarterEnding":"2025/03","expectedEps":-0.19,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1746504000000,"reportTimeType":"post","actualEps":-0.21},{"market":"US","date":"2025-03-20","symbol":"EPRX","fiscalQuarterEnding":"2024/12","expectedEps":null,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1742443200000,"reportTimeType":"post","actualEps":-0.21},{"market":"US","date":"2024-08-07","symbol":"EPRX","fiscalQuarterEnding":"2024/06","expectedEps":null,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1723003200000,"reportTimeType":"post","actualEps":-0.17}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"EPRX\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"EPRX\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.2,"buy":0.8,"hold":0,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":0.8,"analysts":5,"updateTime":1762405200000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/EPRX\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"EPRX","date":"2025-12-05","current":-6.819639,"percent":0.076555,"low":-11.561926,"twenty":-6.97961,"median":-4.181878,"eighty":-3.380077,"high":-2.890365,"avg":-5.204449,"sd":2.286269,"marketCap":292735526.92},"quantilePoints":[{"date":"2024-04-12","current":-3.449431,"twenty":-3.612259,"median":-3.541416,"eighty":-3.493027,"marketCap":97345692.17},{"date":"2024-04-19","current":-3.387698,"twenty":-3.552309,"median":-3.421661,"eighty":-3.370461,"marketCap":95603540.57},{"date":"2024-04-26","current":-3.593562,"twenty":-3.625516,"median":-3.503926,"eighty":-3.385892,"marketCap":101413189.09},{"date":"2024-05-03","current":-3.426605,"twenty":-3.600947,"median":-3.43788,"eighty":-3.383971,"marketCap":96701521.5},{"date":"2024-05-10","current":-3.385898,"twenty":-3.641329,"median":-3.449431,"eighty":-3.385721,"marketCap":102824445.35},{"date":"2024-05-17","current":-3.411647,"twenty":-3.640071,"median":-3.447632,"eighty":-3.387338,"marketCap":103606411.08},{"date":"2024-05-24","current":-3.304959,"twenty":-3.624933,"median":-3.446108,"eighty":-3.385721,"marketCap":100366460.1},{"date":"2024-05-31","current":-3.138144,"twenty":-3.606012,"median":-3.426605,"eighty":-3.379346,"marketCap":95300524.8},{"date":"2024-06-07","current":-3.18109,"twenty":-3.59449,"median":-3.400672,"eighty":-3.300706,"marketCap":96604762.18},{"date":"2024-06-14","current":-3.114449,"twenty":-3.562274,"median":-3.394505,"eighty":-3.199957,"marketCap":94580945.94},{"date":"2024-06-21","current":-3.113503,"twenty":-3.52642,"median":-3.387698,"eighty":-3.149669,"marketCap":94552230.25},{"date":"2024-06-28","current":-2.999703,"twenty":-3.496261,"median":-3.38264,"eighty":-3.125012,"marketCap":91096288.31},{"date":"2024-07-05","current":-3.012181,"twenty":-3.47937,"median":-3.379233,"eighty":-3.113445,"marketCap":91475249.09},{"date":"2024-07-12","current":-3.187556,"twenty":-3.456124,"median":-3.305072,"eighty":-3.105179,"marketCap":96801126.62},{"date":"2024-07-19","current":-2.929989,"twenty":-3.449376,"median":-3.282654,"eighty":-3.095065,"marketCap":88979206.08},{"date":"2024-07-26","current":-3.134177,"twenty":-3.44886,"median":-3.212535,"eighty":-3.063005,"marketCap":95180061.81},{"date":"2024-08-02","current":-3.030624,"twenty":-3.447364,"median":-3.22865,"eighty":-3.063005,"marketCap":92035318.44},{"date":"2024-08-09","current":-3.555022,"twenty":-3.447364,"median":-3.244765,"eighty":-3.058864,"marketCap":95980604.85},{"date":"2024-08-16","current":-3.425897,"twenty":-3.447364,"median":-3.274173,"eighty":-3.063005,"marketCap":92494393.43},{"date":"2024-08-23","current":-3.341671,"twenty":-3.449376,"median":-3.294326,"eighty":-3.065374,"marketCap":90220410.26},{"date":"2024-08-30","current":-3.353652,"twenty":-3.464811,"median":-3.315197,"eighty":-3.071687,"marketCap":90543888.67},{"date":"2024-09-06","current":-3.290695,"twenty":-3.457797,"median":-3.315197,"eighty":-3.093069,"marketCap":88844129.04},{"date":"2024-09-13","current":-3.351624,"twenty":-3.449431,"median":-3.304959,"eighty":-3.103048,"marketCap":90489126.39},{"date":"2024-09-20","current":-3.738594,"twenty":-3.484763,"median":-3.331473,"eighty":-3.103161,"marketCap":100936771.57},{"date":"2024-09-27","current":-3.383135,"twenty":-3.508398,"median":-3.341671,"eighty":-3.113249,"marketCap":91339879.21},{"date":"2024-10-04","current":-3.46667,"twenty":-3.50577,"median":-3.366161,"eighty":-3.11343,"marketCap":93595226.49},{"date":"2024-10-11","current":-3.161762,"twenty":-3.503926,"median":-3.341671,"eighty":-3.113249,"marketCap":85363132.94},{"date":"2024-10-18","current":-3.344907,"twenty":-3.484763,"median":-3.339004,"eighty":-3.11343,"marketCap":90307790.09},{"date":"2024-10-25","current":-3.261872,"twenty":-3.467153,"median":-3.321915,"eighty":-3.113503,"marketCap":88065960.81},{"date":"2024-11-01","current":-4.073023,"twenty":-3.467153,"median":-3.311841,"eighty":-3.114449,"marketCap":109965883.2},{"date":"2024-11-08","current":-3.993124,"twenty":-3.508398,"median":-3.325322,"eighty":-3.122968,"marketCap":112688263.8},{"date":"2024-11-15","current":-3.927702,"twenty":-3.541416,"median":-3.341027,"eighty":-3.124574,"marketCap":110842028.91},{"date":"2024-11-22","current":-4.430924,"twenty":-3.593562,"median":-3.351624,"eighty":-3.128079,"marketCap":125043241.56},{"date":"2024-11-29","current":-4.297671,"twenty":-3.603509,"median":-3.37867,"eighty":-3.132957,"marketCap":121282763.27},{"date":"2024-12-06","current":-3.937318,"twenty":-3.628014,"median":-3.3817,"eighty":-3.136354,"marketCap":111113399.77},{"date":"2024-12-13","current":-4.300289,"twenty":-3.656263,"median":-3.385015,"eighty":-3.137895,"marketCap":121356641.03},{"date":"2024-12-20","current":-3.802924,"twenty":-3.703016,"median":-3.386798,"eighty":-3.142303,"marketCap":107320735.58},{"date":"2024-12-27","current":-3.93234,"twenty":-3.764328,"median":-3.391081,"eighty":-3.149279,"marketCap":110972914.73},{"date":"2025-01-03","current":-3.832661,"twenty":-3.83089,"median":-3.39476,"eighty":-3.153681,"marketCap":108159910.78},{"date":"2025-01-10","current":-3.777243,"twenty":-3.823171,"median":-3.399132,"eighty":-3.154763,"marketCap":106595986.62},{"date":"2025-01-17","current":-4.056922,"twenty":-3.839064,"median":-3.402373,"eighty":-3.156968,"marketCap":114488699.15},{"date":"2025-01-24","current":-3.831634,"twenty":-3.855819,"median":-3.411647,"eighty":-3.159158,"marketCap":108130926.13},{"date":"2025-01-31","current":-3.881124,"twenty":-3.855819,"median":-3.426251,"eighty":-3.159259,"marketCap":109527578.75},{"date":"2025-02-07","current":-4.05521,"twenty":-3.863924,"median":-3.433627,"eighty":-3.159948,"marketCap":114440377.27},{"date":"2025-02-14","current":-4.035949,"twenty":-3.899488,"median":-3.442651,"eighty":-3.161762,"marketCap":113896828.09},{"date":"2025-02-21","current":-4.691735,"twenty":-3.92863,"median":-3.448417,"eighty":-3.164244,"marketCap":132403473.98},{"date":"2025-02-28","current":-4.985728,"twenty":-3.942572,"median":-3.453351,"eighty":-3.171739,"marketCap":140700111.56},{"date":"2025-03-07","current":-5.272628,"twenty":-3.973604,"median":-3.466617,"eighty":-3.179564,"marketCap":148796613.2},{"date":"2025-03-14","current":-5.235352,"twenty":-4.013632,"median":-3.484763,"eighty":-3.186263,"marketCap":147744675.63},{"date":"2025-03-21","current":-5.143943,"twenty":-4.046869,"median":-3.507084,"eighty":-3.193275,"marketCap":131183594.48},{"date":"2025-03-28","current":-4.683166,"twenty":-4.084769,"median":-3.523754,"eighty":-3.206159,"marketCap":119432606.84},{"date":"2025-04-04","current":-4.101903,"twenty":-4.144484,"median":-3.54588,"eighty":-3.211833,"marketCap":104608925.61},{"date":"2025-04-11","current":-4.181878,"twenty":-4.156687,"median":-3.555418,"eighty":-3.233723,"marketCap":106648501.77},{"date":"2025-04-17","current":-4.623736,"twenty":-4.175739,"median":-3.595883,"eighty":-3.239438,"marketCap":117916996.55},{"date":"2025-04-25","current":-5.41667,"twenty":-4.199429,"median":-3.609908,"eighty":-3.239815,"marketCap":138138823.95},{"date":"2025-05-02","current":-5.613333,"twenty":-4.264738,"median":-3.621205,"eighty":-3.242792,"marketCap":143154231.65},{"date":"2025-05-09","current":-5.295999,"twenty":-4.315353,"median":-3.640408,"eighty":-3.244752,"marketCap":138872234.38},{"date":"2025-05-16","current":-5.22877,"twenty":-4.436885,"median":-3.652794,"eighty":-3.248222,"marketCap":137109346.32},{"date":"2025-05-23","current":-5.086528,"twenty":-4.497055,"median":-3.683127,"eighty":-3.254144,"marketCap":133379475.66},{"date":"2025-05-30","current":-5.353206,"twenty":-4.57142,"median":-3.705394,"eighty":-3.256702,"marketCap":140372329.16},{"date":"2025-06-06","current":-5.498899,"twenty":-4.688307,"median":-3.727372,"eighty":-3.257371,"marketCap":144192703.66},{"date":"2025-06-13","current":-5.361342,"twenty":-4.755446,"median":-3.735365,"eighty":-3.25942,"marketCap":140585698.02},{"date":"2025-06-20","current":-6.021317,"twenty":-4.844055,"median":-3.755654,"eighty":-3.26156,"marketCap":157891599.42},{"date":"2025-06-27","current":-6.394464,"twenty":-4.984149,"median":-3.780835,"eighty":-3.263694,"marketCap":167676310.99},{"date":"2025-07-03","current":-7.487464,"twenty":-5.086528,"median":-3.792925,"eighty":-3.270982,"marketCap":196337074.41},{"date":"2025-07-11","current":-7.62232,"twenty":-5.143943,"median":-3.801523,"eighty":-3.275156,"marketCap":199873266.74},{"date":"2025-07-18","current":-7.38883,"twenty":-5.177531,"median":-3.819467,"eighty":-3.277364,"marketCap":193750685.21},{"date":"2025-07-25","current":-7.574057,"twenty":-5.210176,"median":-3.832148,"eighty":-3.277562,"marketCap":198607730.41},{"date":"2025-08-01","current":-7.369401,"twenty":-5.244258,"median":-3.855819,"eighty":-3.290209,"marketCap":193241210.3},{"date":"2025-08-08","current":-7.353701,"twenty":-5.256616,"median":-3.862136,"eighty":-3.290695,"marketCap":192829519.9},{"date":"2025-08-15","current":-6.515547,"twenty":-5.287548,"median":-3.881124,"eighty":-3.293384,"marketCap":188662911.97},{"date":"2025-08-22","current":-6.435294,"twenty":-5.330379,"median":-3.902951,"eighty":-3.294326,"marketCap":186339119.08},{"date":"2025-08-29","current":-6.443249,"twenty":-5.361342,"median":-3.927702,"eighty":-3.29841,"marketCap":186569475.43},{"date":"2025-09-05","current":-6.594946,"twenty":-5.398376,"median":-3.933623,"eighty":-3.303649,"marketCap":190961969.86},{"date":"2025-09-12","current":-6.795439,"twenty":-5.448392,"median":-3.947836,"eighty":-3.305049,"marketCap":196767403.48},{"date":"2025-09-19","current":-7.504554,"twenty":-5.562315,"median":-3.961669,"eighty":-3.315902,"marketCap":217300397.06},{"date":"2025-09-26","current":-7.177732,"twenty":-5.598125,"median":-3.989698,"eighty":-3.321254,"marketCap":207837019.06},{"date":"2025-10-03","current":-10.41009,"twenty":-5.766572,"median":-4.012411,"eighty":-3.324641,"marketCap":301432553.8},{"date":"2025-10-10","current":-10.720754,"twenty":-6.007438,"median":-4.037645,"eighty":-3.335164,"marketCap":310428066.15},{"date":"2025-10-17","current":-10.15161,"twenty":-6.40263,"median":-4.05521,"eighty":-3.339831,"marketCap":293948056.76},{"date":"2025-10-24","current":-9.839558,"twenty":-6.476402,"median":-4.069956,"eighty":-3.341413,"marketCap":284912320.02},{"date":"2025-10-31","current":-9.373299,"twenty":-6.573065,"median":-4.13169,"eighty":-3.34426,"marketCap":271411444.71},{"date":"2025-11-07","current":-9.699849,"twenty":-6.613334,"median":-4.138877,"eighty":-3.350281,"marketCap":284921875.51},{"date":"2025-11-14","current":-10.803812,"twenty":-6.67166,"median":-4.151036,"eighty":-3.353246,"marketCap":317349508.66},{"date":"2025-11-21","current":-10.8778,"twenty":-6.689916,"median":-4.163525,"eighty":-3.373666,"marketCap":319522857.51},{"date":"2025-11-28","current":-10.814452,"twenty":-6.746599,"median":-4.176559,"eighty":-3.379346,"marketCap":317662080.57},{"date":"2025-12-05","current":-9.965856,"twenty":-6.97961,"median":-4.181878,"eighty":-3.380077,"marketCap":292735526.92}],"updateTime":1765229912582},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"EPRX\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2582804472","title":"Eupraxia Pharmaceuticals Up Nearly 16%, on Pace for Largest Percent Increase Since November 2024 -- Data Talk","url":"https://stock-news.laohu8.com/highlight/detail?id=2582804472","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582804472?lang=en_us&edition=fundamental","pubTime":"2025-11-11 03:30","pubTimestamp":1762803000,"startTime":"0","endTime":"0","summary":"Eupraxia Pharmaceuticals, Inc.  is currently at $6.31, up $0.86 or 15.78%. --Would be highest close since Sept. 22, 2025, when it closed at $6.65. --On pace for largest percent increase since Nov. 1, 2024, when it rose 28.36%. --Up 99.05% year-to-date; on pace for best year on record . --Down 6.88% from its all-time closing high of $6.78 on July 6, 2023. --Up 109.63% from 52 weeks ago , when it closed at $3.01. --Traded as high as $6.32; highest intraday level since Sept. 23, 2025, when it hit $6.41","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","EPRX"],"gpt_icon":0},{"id":"2581675747","title":"Eupraxia Pharmaceuticals Q3 EPS $(0.19) Beats $(0.21) Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2581675747","media":"Benzinga","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581675747?lang=en_us&edition=fundamental","pubTime":"2025-11-05 05:43","pubTimestamp":1762292613,"startTime":"0","endTime":"0","summary":"Eupraxia Pharmaceuticals Q3 EPS $(0.19) Beats $(0.21) Estimate","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/25/11/48639239/eupraxia-pharmaceuticals-q3-eps-0-19-beats-0-21-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Eupraxia Pharmaceuticals Q3 EPS $(0.19) Beats $(0.21) Estimate","news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["EPRX"],"gpt_icon":0},{"id":"2581767111","title":"Eupraxia Pharmaceuticals Reports Third Quarter 2025 Financial Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2581767111","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581767111?lang=en_us&edition=fundamental","pubTime":"2025-11-05 05:39","pubTimestamp":1762292340,"startTime":"0","endTime":"0","summary":"Durable symptom and tissue responses observed out to 52 weeks following a single treatment with EP-104GI Enrollment continues in Phase 2b portion of the RESOLVE Trial, with topline data expected by Q3","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/11/04/3180937/0/en/Eupraxia-Pharmaceuticals-Reports-Third-Quarter-2025-Financial-Results.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["EPRX","BK4139"],"gpt_icon":0},{"id":"2581762090","title":"Eupraxia Pharmaceuticals Releases Q3 2025 Financial Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2581762090","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581762090?lang=en_us&edition=fundamental","pubTime":"2025-11-05 05:33","pubTimestamp":1762292015,"startTime":"0","endTime":"0","summary":"Eupraxia Pharmaceuticals ( ($TSE:EPRX) ) has shared an update. Eupraxia Pharmaceuticals Inc. released its consolidated financial statements and man...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/eupraxia-pharmaceuticals-releases-q3-2025-financial-results?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/eupraxia-pharmaceuticals-releases-q3-2025-financial-results?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","EPRX"],"gpt_icon":0},{"id":"2578620112","title":"Eupraxia Pharmaceuticals Advances EoE Treatment with EP-104GI Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2578620112","media":"TIPRANKS","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2578620112?lang=en_us&edition=fundamental","pubTime":"2025-10-28 03:38","pubTimestamp":1761593885,"startTime":"0","endTime":"0","summary":"Eupraxia Pharmaceuticals, Inc. (($TSE:EPRX)) announced an update on their ongoing clinical study. Study Overview: Eupraxia Pharmaceuticals, Inc. is...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/eupraxia-pharmaceuticals-advances-eoe-treatment-with-ep-104gi-trial?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/eupraxia-pharmaceuticals-advances-eoe-treatment-with-ep-104gi-trial?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["EP","EPRX","BK4139","BK4213"],"gpt_icon":0},{"id":"2572558958","title":"Eupraxia Pharmaceuticals Reports Positive Results in EoE Trial and Plans Expansion","url":"https://stock-news.laohu8.com/highlight/detail?id=2572558958","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2572558958?lang=en_us&edition=fundamental","pubTime":"2025-10-01 23:18","pubTimestamp":1759331901,"startTime":"0","endTime":"0","summary":"An update from Eupraxia Pharmaceuticals ( ($TSE:EPRX) ) is now available. On September 29, 2025, Eupraxia Pharmaceuticals announced positive data f...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/eupraxia-pharmaceuticals-reports-positive-results-in-eoe-trial-and-plans-expansion?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/eupraxia-pharmaceuticals-reports-positive-results-in-eoe-trial-and-plans-expansion?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","EPRX"],"gpt_icon":0},{"id":"2571032258","title":"Raymond James Sticks to Their Buy Rating for Eupraxia Pharmaceuticals (EPRX)","url":"https://stock-news.laohu8.com/highlight/detail?id=2571032258","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2571032258?lang=en_us&edition=fundamental","pubTime":"2025-09-30 23:35","pubTimestamp":1759246535,"startTime":"0","endTime":"0","summary":"In a report released today, from Raymond James reiterated a Buy rating on Eupraxia Pharmaceuticals, with a price target of $12.00. The company’s sh...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/raymond-james-sticks-to-their-buy-rating-for-eupraxia-pharmaceuticals-eprx-blurbs?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/raymond-james-sticks-to-their-buy-rating-for-eupraxia-pharmaceuticals-eprx-blurbs?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["EPRX","RJF"],"gpt_icon":0},{"id":"2571936370","title":"Eupraxia Pharmaceuticals Closes $80.5 Million Public Offering","url":"https://stock-news.laohu8.com/highlight/detail?id=2571936370","media":"TIPRANKS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2571936370?lang=en_us&edition=fundamental","pubTime":"2025-09-30 05:06","pubTimestamp":1759179964,"startTime":"0","endTime":"0","summary":"Eupraxia Pharmaceuticals ( ($TSE:EPRX) ) has provided an update. On September 24, 2025, Eupraxia Pharmaceuticals Inc. announced the successful clos...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/eupraxia-pharmaceuticals-closes-80-5-million-public-offering?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/eupraxia-pharmaceuticals-closes-80-5-million-public-offering?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["EPRX","BK4139"],"gpt_icon":0},{"id":"2571363471","title":"Eupraxia Pharmaceuticals Announces Positive Data from Highest-Dose Cohort in the Ongoing RESOLVE Trial in Eosinophilic Esophagitis, and Plans for Expansion of EP-104GI Development Programs","url":"https://stock-news.laohu8.com/highlight/detail?id=2571363471","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2571363471?lang=en_us&edition=fundamental","pubTime":"2025-09-30 05:00","pubTimestamp":1759179600,"startTime":"0","endTime":"0","summary":"Clinical data was reported for the first time in patients receiving an 8 mg dose per injection (Cohort 9 of the dose escalation portion of RESOLVE), the highest dose planned in this trial. Patients in","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/09/29/3158170/0/en/Eupraxia-Pharmaceuticals-Announces-Positive-Data-from-Highest-Dose-Cohort-in-the-Ongoing-RESOLVE-Trial-in-Eosinophilic-Esophagitis-and-Plans-for-Expansion-of-EP-104GI-Development-P.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4213","EPRX","BK4139","EP"],"gpt_icon":0},{"id":"2569702683","title":"Eupraxia Pharmaceuticals Closes $80.5 Million Public Offering","url":"https://stock-news.laohu8.com/highlight/detail?id=2569702683","media":"MT Newswires Live","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2569702683?lang=en_us&edition=fundamental","pubTime":"2025-09-24 21:24","pubTimestamp":1758720297,"startTime":"0","endTime":"0","summary":"Eupraxia Pharmaceuticals  said Wednesday that it has closed its public offering of about 14.6 million common shares priced at $5.50 per share, with the underwriters fully exercising an option to buy additional shares.The company said it raised about $80.5 million in gross proceeds. Net proceeds will be used for further development of its product pipeline, research and development of additional pipeline candidates, business development activities, and general corporate purposes, the company added.Shares of Eupraxia Pharmaceuticals were up more than 12% in recent Wednesday premarket activity.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["EPRX","BK4139"],"gpt_icon":0},{"id":"2569148712","title":"Eupraxia Pharmaceuticals Down Over 7%, on Pace for Largest Percent Decrease Since March 2024 -- Data Talk","url":"https://stock-news.laohu8.com/highlight/detail?id=2569148712","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2569148712?lang=en_us&edition=fundamental","pubTime":"2025-09-24 00:44","pubTimestamp":1758645840,"startTime":"0","endTime":"0","summary":"Eupraxia Pharmaceuticals, Inc.  is currently at C$8.19, down C$0.68 or 7.67%. --On pace for largest percent decrease since March 12, 2024, when it fell 33.33%. --Up 10.38% month-to-date; on pace for best month since June 2025, when it rose 46.82%. --Down 7.98% from its all-time closing high of C$8.90 on July 7, 2023. --Up 121.35% from 52 weeks ago , when it closed at C$3.70. --Down 10.03% at today's intraday low; largest intraday percent decrease since July 21, 2025, when it fell as much as 10.97%","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["EPRX","BK4139"],"gpt_icon":0},{"id":"2569711754","title":"Eupraxia Pharmaceuticals Prices $70 Million Public Offering","url":"https://stock-news.laohu8.com/highlight/detail?id=2569711754","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2569711754?lang=en_us&edition=fundamental","pubTime":"2025-09-23 23:27","pubTimestamp":1758641237,"startTime":"0","endTime":"0","summary":"Eupraxia Pharmaceuticals ( ($TSE:EPRX) ) has shared an announcement. On September 22, 2025, Eupraxia Pharmaceuticals announced the pricing of a pub...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/eupraxia-pharmaceuticals-prices-70-million-public-offering?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/eupraxia-pharmaceuticals-prices-70-million-public-offering?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","EPRX"],"gpt_icon":0},{"id":"2569799078","title":"Eupraxia Pharmaceuticals 12.727M share Spot Secondary priced at $5.50","url":"https://stock-news.laohu8.com/highlight/detail?id=2569799078","media":"TIPRANKS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2569799078?lang=en_us&edition=fundamental","pubTime":"2025-09-23 18:20","pubTimestamp":1758622828,"startTime":"0","endTime":"0","summary":"Cantor Fitzgerald and LifeSci Capital acted as joint book running managers for the offering. Published first on TheFly – the ultimate source for re...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/eupraxia-pharmaceuticals-12-727m-share-spot-secondary-priced-at-5-50-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/eupraxia-pharmaceuticals-12-727m-share-spot-secondary-priced-at-5-50-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["EPRX","BK4139"],"gpt_icon":0},{"id":"2569730181","title":"Eupraxia Pharmaceuticals Proposes Public Offering","url":"https://stock-news.laohu8.com/highlight/detail?id=2569730181","media":"MT Newswires Live","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2569730181?lang=en_us&edition=fundamental","pubTime":"2025-09-23 04:24","pubTimestamp":1758572640,"startTime":"0","endTime":"0","summary":"Eupraxia Pharmaceuticals  said late Monday it has filed a preliminary prospectus supplement to its short form base shelf prospectus for a public offering of shares.The firm expects to grant its underwriters a 30-day option to buy up to an additional 15% of shares offered in the offering.Shares were over 2% lower in after-market activity.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4139","EPRX"],"gpt_icon":0},{"id":"2569073092","title":"Eupraxia Pharmaceuticals announces common shares offering, no amount given","url":"https://stock-news.laohu8.com/highlight/detail?id=2569073092","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2569073092?lang=en_us&edition=fundamental","pubTime":"2025-09-23 04:10","pubTimestamp":1758571838,"startTime":"0","endTime":"0","summary":"Eupraxia Pharmaceuticals (EPRX) has filed a preliminary prospectus supplement to its short form base shelf prospectus dated February 5, 2024 in con...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/eupraxia-pharmaceuticals-announces-common-shares-offering-no-amount-given-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/eupraxia-pharmaceuticals-announces-common-shares-offering-no-amount-given-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","EPRX"],"gpt_icon":0},{"id":"2569212730","title":"Eupraxia Pharmaceuticals Announces Proposed Public Offering of Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2569212730","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2569212730?lang=en_us&edition=fundamental","pubTime":"2025-09-23 04:01","pubTimestamp":1758571260,"startTime":"0","endTime":"0","summary":"VICTORIA, British Columbia, Sept.  22, 2025  (GLOBE NEWSWIRE) -- Eupraxia Pharmaceuticals Inc.(“Eupraxia” or the “Company”) (NASDAQ:EPRX) (TSX:EPRX), a clinical-stage biotechnology company leveraging ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/09/22/3154291/0/en/Eupraxia-Pharmaceuticals-Announces-Proposed-Public-Offering-of-Common-Shares.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["EPRX","BK4139"],"gpt_icon":0},{"id":"2568729991","title":"Eupraxia Pharmaceuticals Appoints New CFO Amid Leadership Transition","url":"https://stock-news.laohu8.com/highlight/detail?id=2568729991","media":"TIPRANKS","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2568729991?lang=en_us&edition=fundamental","pubTime":"2025-09-20 04:17","pubTimestamp":1758313031,"startTime":"0","endTime":"0","summary":"An update from Eupraxia Pharmaceuticals ( ($TSE:EPRX) ) is now available. On February 18, 2025, Eupraxia Pharmaceuticals announced the appointment ...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/eupraxia-pharmaceuticals-appoints-new-cfo-amid-leadership-transition?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/eupraxia-pharmaceuticals-appoints-new-cfo-amid-leadership-transition?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["EPRX","BK4139"],"gpt_icon":0},{"id":"2564040818","title":"First Set of 1-Year Clinical Results from RESOLVE Trial in Eosinophilic Esophagitis (EoE), Durable and Sustained Symptom & Tissue Responses after Dosing with EP-104GI","url":"https://stock-news.laohu8.com/highlight/detail?id=2564040818","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2564040818?lang=en_us&edition=fundamental","pubTime":"2025-09-02 20:00","pubTimestamp":1756814400,"startTime":"0","endTime":"0","summary":"At 12 months, 2/3rds of Cohort 5 patients (48mg dose, 4mg per site) remained in clinical remission after their treatment with EP-104GIAll Cohorts followed to 9 months have maintained clinically meanin","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/09/02/3142594/0/en/First-Set-of-1-Year-Clinical-Results-from-RESOLVE-Trial-in-Eosinophilic-Esophagitis-EoE-Durable-and-Sustained-Symptom-Tissue-Responses-after-Dosing-with-EP-104GI.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4213","EP","EPRX","BK4139"],"gpt_icon":0},{"id":"2560917223","title":"Eupraxia Pharmaceuticals Price Target Maintained With a $12.00/Share by HC Wainwright & Co.","url":"https://stock-news.laohu8.com/highlight/detail?id=2560917223","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2560917223?lang=en_us&edition=fundamental","pubTime":"2025-08-20 18:42","pubTimestamp":1755686520,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/EPRX/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  August 20, 2025 06:42 ET (10:42 GMT)","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["EPRX"],"gpt_icon":0},{"id":"2559162226","title":"Eupraxia Pharmaceuticals Q2 EPS $(0.26) Misses $(0.19) Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2559162226","media":"Benzinga","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2559162226?lang=en_us&edition=fundamental","pubTime":"2025-08-13 06:03","pubTimestamp":1755036207,"startTime":"0","endTime":"0","summary":"Eupraxia Pharmaceuticals (NASDAQ:EPRX) reported quarterly losses of $(0.26) per share which missed the analyst consensus estimate of $(0.19) by 36.84 percent. This is a 52.94 percent decrease over losses of $(0.17) per","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/25/08/47078008/eupraxia-pharmaceuticals-q2-eps-0-26-misses-0-19-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Eupraxia Pharmaceuticals Q2 EPS $(0.26) Misses $(0.19) Estimate","news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["EPRX"],"gpt_icon":0}],"pageSize":20,"totalPage":2,"pageCount":1,"totalSize":24,"code":"91000000","status":"200"}]}}